1. A battery charger comprising:
a circuit, and
a plurality of charging pins,
the circuit comprising a microcontroller,
each pin of the plurality of charging pins electrically coupled to the circuit,
where the microcontroller sets a state of each charging pin of the plurality of charging pins.
2. The battery charger of claim 1 where the state of each charging pin is selected from the group consisting of a positive pin, a ground pin, a communications pin, a trigger pin, and an unused pin.
3. The battery charger of claim 1 where the microcontroller sets the state of each charging pin of the plurality of charging pins after determining which charging pin of the plurality of charging pins is in electrical contact with a trigger contact of a device.
4. The battery charger of claim 1 where the plurality of charging pins are arranged such that they exhibit approximate rotational symmetry around a point.
5. The battery charger of claim 1 further comprising an electrical connector.
6. The battery charger of claim 1, further comprising a magnet positioned against the body such that a magnetic field of the magnet attracts a device against the tips of the plurality of charging pins.
7. The battery charger of claim 6 where the magnet comprises one or more holes arranged such that one or more of the plurality of charging pins passes through at least one of the one or more holes.
8. A battery charger comprising:
a body,
an electrical connector,
a circuit, and
a plurality of charging pins,
the circuit comprising a microcontroller,
the electrical connector electrically coupled to the circuit,
the body comprising a cavity having a rear surface,
each pin of the plurality of charging pins electrically coupled to the microcontroller,
the plurality of charging pins disposed such that a tip of each charging pin of the plurality of charging pins extend above the rear surface of the cavity,
where the microcontroller sets a state of each charging pin of the plurality of charging pins.
9. The battery charger of claim 8 where the state of each charging pin is selected from the group consisting of a positive pin, a ground pin, a communications pin, a trigger pin, and an unused pin.
10. The battery charger of claim 8 where the microcontroller sets the state of each charging pin of the plurality of charging pins after determining which charging pin of the plurality of charging pins is in electrical contact with a trigger contact of a device.
11. The battery charger of claim 8 where the plurality of charging pins are arranged such that they exhibit approximate rotational symmetry around a point.
12. The battery charger of claim 8 further comprising a first plurality of load switches and a second plurality of load switches, the number of load switches of the first plurality of load switches equal to the number of charging pins of the plurality of charging pins, the number of load switches of the second plurality of load switches equal to the number of charging pins of the plurality of charging pins, where each charging pin of the plurality of charging pins is electrically connected to a load switch of the first plurality of load switches, and each load switch of the first plurality of load switches is electrically connected to a charging pin of the plurality of charging pins, and where each charging pin of the plurality of charging pins is electrically connected to a load switch of the second plurality of load switches, and each load switch of the second plurality of load switches is electrically connected to a charging pin of the plurality of charging pins, and each load switch of the first plurality of load switches is electrically connected to the microcontroller, and each load switch of the second plurality of load switches is electrically connected to the microcontroller; and
where when the circuit is energized, the microcontroller senses a voltage from each charging pin of the plurality of charging pins until a voltage within a voltage range is detected from one charging pin of the plurality of charging pins, whereupon the microcontroller sets the state of each charging pin of the plurality of charging pins according to a predetermined relative layout by enabling a subset of load switches of the first plurality of load switches and the second plurality of load switches.
13. The battery charger of claim 12 further comprising a power-on-reset controller and a third plurality of load switches, where the power-on-reset controller is electrically coupled to the microcontroller, and where each charging pin of the plurality of charging pins is electrically connected to a load switch of the third plurality of load switches, and each load switch of the third plurality of load switches is electrically connected to a charging pin of the plurality of charging pins, and each load switch of the third plurality of load switches is electrically connected to the power-on-reset controller; and where the power-on-reset controller resets the circuit when power is connected to the electrical connector.
14. A method for operating a battery charger, the method comprising:
detecting a device coupling to the battery charger,
scanning a plurality of voltages from a plurality of electrical lines,
evaluating which voltage of the plurality of voltages is within a predetermined voltage range,
determining an orientation of the device based upon the voltage that is within the predetermined voltage range, and
configuring a state of each electrical line of the plurality of electrical lines according to a predetermined pattern relative to the orientation.
15. The method for operating a battery charger of claim 14 further comprising:
detecting a voltage of an electrical line corresponding to a battery of the device, and
when the voltage is below a threshold then setting a charge controller to a charging state.
16. The method for operating a battery charger of claim 14 further comprising:
detecting a voltage of an electrical line corresponding to a battery of the device, and
when the voltage exceeds a threshold then setting the charge controller to a maintenance state.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula (I),
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein
each n is an integer with value 0, 1 or 2 and when n is 0 then a direct bond is intended;
each m is an integer with value 1 or 2;
each X is independently N or CH;
each Y is independently O, S, or NR4; wherein
each R4 is hydrogen, C1-6alkyl, C1-6alkyloxyC1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylmethyl, phenylC1-6alkyl, \u2014C(\u2550O)\u2014CHR5R6 or \u2014S(\u2550O)2\u2014N(CH3)2; wherein
each R5 and R6 is independently hydrogen, amino, C1-6alkyl or aminoC1-6alkyl; and
when Y is NR4 and R2 is on the 7-position of the indolyl then R2 and R4 together can form the bivalent radical
\u2014(CH2)2\u2014\u2003\u2003(a-1), or
\u2014(CH2)3\u2014\u2003\u2003(a-2);
R1 is hydrogen, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkylsulfonyl, C1-6alkylcarbonyl or mono- or di(C1-6alkyl)aminosulfonyl;
R2 is hydrogen, hydroxy, amino, halo, C1-6alkyl, cyano, C2-6alkenyl, polyhaloC1-6alkyl, nitro, phenyl, C1-6alkylcarbonyl, hydroxycarbonyl, C1-6alkylcarbonylamino, C1-6alkyloxy, or mono- or di(C1-6alkyl)amino;
R3 is hydrogen, C1-6alkyl, or C1-6alkyloxy; and
when R2 and R3 are on adjacent carbon atoms, they can form the bivalent radical \u2014O\u2014CH2\u2014O\u2014.
2. A compound according to claim 1 wherein
each n is an integer with value 0 or 1; each R4 is hydrogen, C1-6alkyl, C1-6alkyloxyC1-6alkyl, C3-6cycloalkyl or phenylC1-6alkyl; R1 is hydrogen, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkylcarbonyl or C1-6alkylsulfonyl; and R2 is hydrogen, halo, C1-6alkyl, cyano, nitro, polyhaloC1-6alkyl or C1-6alkyloxy.
3. A compound according to claim 1 wherein
wherein each n is an integer with value 1; each m is an integer with value 1; each X is independently N; each Y is independently NR4; each R4 is C1-6alkyl; R1 is hydrogen; R2 is hydrogen or halo; and R3 is hydrogen.
4. A compound selected from the group consisting of compound No. 1a, compound No. 30, compound No. 39 and compound No. 50:
and the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof.
5. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 1.
6. A process of preparing a pharmaceutical composition as claimed in claim 5 wherein the pharmaceutically acceptable carriers and the compound as claimed in claim 5 are intimately mixed.
7. A combination of an anti-cancer agent and a compound as claimed in claim 1.
8. A process for preparing a compound as claimed in claim 1, said process comprising the steps of:
a) reacting an intermediate of formula (II), wherein Q is tetrahydropyranyloxyaminocarbonyl, herein referred to as an intermediate of formula (II-a), with trifluoro acetic acid, yielding a hydroxamic acid of formula (I)
b) reacting an intermediate of formula (II), wherein Q is C1-2alkyloxycarbonyl, herein referred to as intermediates of formula (II-c), with hydroxylamine, in the presence of a base and in methanol with the production of a hydroxamic acid of formula (I)
9. A compound of formula (II),
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein
each n is an integer with value 0, 1 or 2 and when n is 0 then a direct bond is intended;
each m is an integer with value 1 or 2;
each X is independently N or CH;
each Y is independently O, S, or NR4; wherein
each R4 is hydrogen, C1-6alkyl, C1-6alkyloxyC1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylmethyl, phenylC1-6alkyl, \u2014C(\u2550O)\u2014CHR5R6 or \u2014S(\u2550O)2\u2014N(CH3)2; wherein
each R5 and R6 is independently hydrogen, amino, C1-6alkyl or aminoC1-6alkyl; and
when Y is NR4 and R2 is on the 7-position of the indolyl then R2 and R4 together can form the bivalent radical
\u2014(CH2)2\u2014\u2003\u2003(a-1), or
\u2014(CH2)3\u2014\u2003\u2003(a-2);
R1 is hydrogen, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkylsulfonyl, C1-6alkylcarbonyl or mono- or di(C1-6alkyl)aminosulfonyl;
R2 is hydrogen, hydroxy, amino, halo, C1-6alkyl, cyano, C2-6alkenyl, polyhaloC1-6alkyl, nitro, phenyl, C1-6alkylcarbonyl, hydroxycarbonyl, C1-6alkylcarbonylamino, C1-6alkyloxy, or mono- or di(C1-6alkyl)amino;
R3 is hydrogen, C1-6alkyl, or C1-6alkyloxy;
when R2 and R3 are on adjacent carbon atoms, they can form the bivalent radical \u2014O\u2014CH2\u2014O\u2014; and
Q is C1-2alkyloxycarbonyl, hydroxycarbonyl or tetrahydropyranyloxyaminocarbonyl.
10. A process for preparing a compound as claimed in claim 9, said process comprising the steps of:
a) reacting a compound of formula (II), wherein Q is hydroxycarbonyl, herein referred to as compounds of formula (II-b), with an intermediate of formula (III) in the presence of reagents comprising N\u2032-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine, monohydrochloride (EDC) or 1-hydroxy-1H-benzotriazole (HOBT) with the formation of a compound of formula (II-a),
b) reacting an intermediate of formula (VI) with the carboxaldehyde of formula (V), wherein t is an integer with value 0 or 1, and when t is 0 then a direct bond is intended, in the presence of sodium borohydride, with the formation of a compound of formula (II-a),
c) reacting a compound of formula (II), wherein Q is methyl- or ethyloxycarbonyl (C1-2alkyl), herein referred to as compounds of formula (II-c), with an acidic solution or basic solution, with the formation of a compound of formula (II-b),
d) reacting the carboxylic acid ethyl ester of formula (IV) with the carboxaldehyde of formula (V), in the presence of sodium borohydride in methanol, with the formation of a compound of formula (II-c),
e) reacting an intermediate of formula (XIV) with the intermediate of formula (XV), in the presence of sodium borohydride in methanol,
with the formation of a compound of formula (II-c),
f) reacting an intermediate of formula (X) with an intermediate of formula (XI) wherein W is group comprising fluoro, chloro, bromo or iodo, or methylsulfonyloxy, with the formation of a compound of formula (II-c), or
g) reacting an intermediate of formula (XII) with an intermediate of formula (XIII), wherein W described above, with the formation of a compound of formula (II-c)
11. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 2.
12. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 3.
13. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 4.
14. A combination of an anti-cancer agent and a compound as claimed in claim 2.
15. A combination of an anti-cancer agent and a compound as claimed in claim 3.
16. A combination of an anti-cancer agent and a compound as claimed in claim 4.
17. A compound of the following structure:
and the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof.
18. A compound selected from the group consisting of:
and the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof.
19. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 17.
20. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 18.
21. A combination of an anti-cancer agent and a compound as claimed in claim 17.
22. A combination of an anti-cancer agent and a compound as claimed in claim 18.
23. The combination of claim 7, wherein said anti-cancer agent is a DNA methyl transferase inhibitors.
24. The combination of claim 21, wherein said anti-cancer agent is a DNA methyl transferase inhibitors.
25. The combination of claim 22, wherein said anti-cancer agent is a DNA methyl transferase inhibitors.